New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
January 16, 2025 - The FDA approved Azurity Pharmaceuticals’ Brynovin (sitagliptin) oral solution, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Download PDF
Return to publications
